non-small cell lung cancer stages IIIA (N2) and selected resectable stages IIIB
Conditions
Brief summary
The primary endpoint is the progression-free survival rate
Detailed description
Overall survival, Occurrence of pulmonary adverse effects of grade > 3 according to CTCAE 5.0., Occurrence of immune therapy related adverse effects of grade > 3 according to CTCAE v.5.0., Adverse events with at least probable relationship to study procedures will counted in total and separate according to CTCAE criteria., Quality of life (QoL C30 and Qol-LC13) date will be analyzed descriptively calculation mean scores, standard deviations median minimum and maximum of the scores.
Interventions
DRUGIMFINZI 50 mg/mL concentrate for solution for infusion.
Sponsors
Universitaetsklinikum Essen AöR
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is the progression-free survival rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival, Occurrence of pulmonary adverse effects of grade > 3 according to CTCAE 5.0., Occurrence of immune therapy related adverse effects of grade > 3 according to CTCAE v.5.0., Adverse events with at least probable relationship to study procedures will counted in total and separate according to CTCAE criteria., Quality of life (QoL C30 and Qol-LC13) date will be analyzed descriptively calculation mean scores, standard deviations median minimum and maximum of the scores. | — |
Countries
Germany
Outcome results
None listed